Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma: an Open-label, Single Arm, Phase II Trial
Latest Information Update: 26 Jul 2021
At a glance
- Drugs Camrelizumab (Primary) ; Decitabine (Primary) ; Tucidinostat (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 08 Jun 2021 Results (n=19) assessing safety and efficacy of the combination of decitabine-plus-camrelizumab and chidamide in decitabine-plus-camrelizumab resistant classical Hodgkin lymphoma patients, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
- 12 Aug 2020 Planned number of patients changed from 280 to 100.
- 23 Jan 2020 New trial record